UNSPSC 51373470: Homatropine/hydrocodone

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373470 Homatropine/hydrocodone is a Commodity code covering pharmaceutical products, though recent state and local procurement activity under this code shows limited direct alignment with the code's nominal scope. The two recent opportunities tagged to this code involve naloxone and safe drug deactivation systems (Seminole County, Florida) and generic multi-source pharmaceuticals and over-the-counter products distributed through authorized wholesalers (Minnesota Multistate Cooperative Purchasing Alliance). The issuing bodies are mixed — a county health department and a state-administered cooperative purchasing alliance — but the opportunities reflect procurement of finished pharmaceutical products and medical systems for distribution to public health facilities and member jurisdictions rather than the specific branded pharmaceutical formulation the code nominally describes.

Seminole County, Florida and the Minnesota Department of Administration's MMCAP cooperative are the two principal issuers with recent activity. The Seminole County IFB (IFB60459723LAS, due July 26, 2026) seeks annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to the county's community health building; vendors must submit unit pricing and comply with E-Verify and drug-free workplace certification. The MMCAP RFP (S1070000015802, due March 26, 2026) establishes multi-award contracts for generic pharmaceuticals and OTC products distributed across Minnesota, Oregon, and participating state and local facilities through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co.). Vendors responding to MMCAP must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain relationships with at least two of the three authorized wholesalers, and accept a 3 percent administrative fee; pricing is weighted at 75 percent of evaluation. The code shows limited recent activity and unclear relevance to homatropine/hydrocodone specifically; business development professionals should verify the actual pharmaceutical products their firm supplies against the specific product line items in open RFPs rather than rely on this code's nominal classification.